Aptose Biosciences Inc. 8-K

What Happened Aptose Biosciences, Inc. (APTOF) filed a Form 8-K on March 23, 2026 (Item 7.01) to disclose a press release issued the same day under Regulation FD. The press release is attached to the filing as Exhibit 99.1 and the company notes the release is furnished (not “filed”) for purposes of Section 18 of the Exchange Act. The filing also includes the Inline XBRL cover page (Exhibit 104).

Key Details

• Filing date: March 23, 2026 (Form 8-K, Item 7.01).
• Press release attached as Exhibit 99.1 and explicitly furnished under Regulation FD.
• Company statement: information in the press release is not deemed “filed” for Section 18 liability or incorporated by reference unless expressly stated.
• Inline XBRL cover page included as Exhibit 104.

Why It Matters This filing notifies investors that Aptose publicly released information on March 23, 2026 in a manner consistent with Regulation FD, which aims to ensure fair disclosure to the market. The 8-K does not itself report earnings, financial results, management changes, or other material facts beyond the attached press release; investors should read Exhibit 99.1 for the substantive content of the announcement.